New antibiotic cocktail takes on superbug pneumonia in hospitals
NCT ID NCT07326540
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 3 trial tests a new antibiotic combination (BV100 plus low-dose polymyxin B) against a standard treatment (colistin plus ampicillin/sulbactam) for hospital-acquired or ventilator-associated pneumonia caused by a drug-resistant bacteria called CRABC. The study will enroll 248 adults and measure survival rates at 28 days. It aims to find a safer and more effective way to treat this serious infection.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- BV100 (an antibiotic) plus low-dose polymyxin B
- What this could lead to
- If successful, this could provide a new treatment option for a hard-to-treat, drug-resistant pneumonia in hospitalized patients.
- What could go wrong
- This is a phase 3 trial, but results are not yet known. The new combination may not be more effective or safer than existing treatments, and side effects from the antibiotics are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACINETOBACTER BAUMANNII-CALCOACETICUS COMPLEX are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
University Hospital
RECRUITINGTbilisi, Georgia
More trials for these conditions
Other studies related to the condition(s) this trial covers.